Shattuck Labs Announces Participation in Upcoming January Investor Conferences

AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022.  

Presentation Details

Conference: H.C. Wainwright BioConnect 2022 ConferenceFormat: Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: January 10, 2022Time: 7:00 a.m. EST

Conference: 40th Annual J.P. Morgan Healthcare ConferenceFormat: Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: January 13, 2022Time: 11:15 a.m. EST

A live webcast of both presentations will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact: Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.[email protected]

Media Contact:Stephanie Ascher Managing DirectorStern Investor Relations, Inc.[email protected]

You May Also Be Interested In

• FORVIA: Total number of voting rights and shares forming the share capital
• Mason Cisney Alcon Wealth Management Group Joins UBS in Pueblo, CO
• Tetragon Financial Group Limited Announcement of Final Results of Tender Offer to Purchase Tetragon Non-Voting Shares